National Psoriasis Foundation

 

Biologic Drugs: Fact Sheets

Enbrel (etanercept)

  • FDA-approved for treating psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis
  • Patients give themselves an injection once or twice a week
  • Taken continuously to maintain results
  • May reduce the progression of joint damage
  • Occasional blood tests are recommended

Download the Enbrel fact sheet (pdf) »


Humira (adalimumab)

  • FDA-approved for treating psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis
  • Individuals give themselves an injection usually every other week
  • Patients should be screened for latent (hidden) tuberculosis (TB) before taking Humira
  • May reduce the progression of joint damage
  • Occasional blood tests are recommended

If you take Humira and recently received a letter from United Healthcare indicating they will no longer provide coverage, call 1.800.4.HUMIRA (448.6472) to discuss how to obtain or continue co-pay assistance.

Download the Humira fact sheet (pdf) »


Remicade (infliximab)

  • FDA-approved for psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis and Crohn's disease
  • Given by three infusions in a doctor's office during the first six weeks of treatment
  • Later infusions repeated every eight weeks
  • Patients should be screened for latent (hidden) tuberculosis (TB) before taking infliximab
  • May reduce the progression of joint damage
  • Blood tests are recommended on a regular basis

Download the Remicade fact sheet (pdf) »


Simponi (golimumab)

  • FDA-approved for psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis
  • Patients give themselves an injection one time per month
  • Patients should be screened for latent (hidden) tuberculosis (TB) before taking
  • May reduce the progression of joint damage
  • Blood tests are recommended on a regular basis

Download the Simponi fact sheet (pdf) »


Stelara (ustekinumab)

  • FDA-approved for plaque psoriasis and psoriatic arthritis
  • After two initial doses at weeks 0 and 4, patients receive an injection by a health care provider once every 12 weeks
  • Patients should be screened for latent (hidden) tuberculosis (TB) before taking Stelara
  • Occasional blood tests are recommended

Download the Stelara fact sheet (pdf) »

National Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.